Dog · Canis lupus familiaris · typical adult weight 2.00–80.00 kg
Mavacoxib is dosed at 2 mg/kg PO Day 0, Day 14, then monthly (max 7 doses) in dogs, per Cox SR, Lesman SP, Boucher JF et al. (2010) The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs. Journal of Veterinary Pharmacology and Therapeutics 33, 461-470 | Cox SR, Liao S, Payne-Johnson M et al. (2011) Population pharmacokinetics of mavacoxib in osteoarthritic dogs. Journal of Veterinary Pharmaology and Therapeutics 34, 1-11 doi:10.1111/j.1365-2885.2010.01165.x — Verified against BSAVA Small Animal Formulary, 10th Ed, Part A, p.263 (2026-08-01). — LOCATOR CONVENTION 2026-08-07: the bare 'p.263' in this citation is the PDF index of the held scan, not the printed page. The PRINTED page is p.247; verified by finding the drug named there. If you are holding the book, turn to p.247. — SOURCE EDITION: BSAVA Small Animal Formulary, Part A — Canine and Feline — ISBN 9781910443705, https://openlibrary.org/isbn/9781910443705; Veterinary Pharmacology and Therapeutics — ISBN 9781118855829, https://openlibrary.org/isbn/9781118855829. Mavacoxib is used in dogs for Osteoarthritis (long-term). Routes documented in dogs: PO. A typical adult dog weighs 2.00–80.00 kg. ExoticRx lists 1 cited dose rule for Mavacoxib in dogs, drawn from published veterinary references. Verify against current literature before clinical use.
US trade names: Trocoxil
| Route | Dose | Frequency | Duration |
|---|
| Indication |
|---|
| Evidence |
|---|
| Source |
|---|
| PO | 2 mg/kg | Day 0, Day 14, then monthly (max 7 doses) | Maximum 6.5 months continuous treatment | Osteoarthritis (long-term) | Strong | Cox SR, Lesman SP, Boucher JF et al. (2010) The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs. Journal of Veterinary Pharmacology and Therapeutics 33, 461-470 | Cox SR, Liao S, Payne-Johnson M et al. (2011) Population pharmacokinetics of mavacoxib in osteoarthritic dogs. Journal of Veterinary Pharmaology and Therapeutics 34, 1-11 doi:10.1111/j.1365-2885.2010.01165.x — Verified against BSAVA Small Animal Formulary, 10th Ed, Part A, p.263 (2026-08-01). — LOCATOR CONVENTION 2026-08-07: the bare 'p.263' in this citation is the PDF index of the held scan, not the printed page. The PRINTED page is p.247; verified by finding the drug named there. If you are holding the book, turn to p.247. — SOURCE EDITION: BSAVA Small Animal Formulary, Part A — Canine and Feline — ISBN 9781910443705, https://openlibrary.org/isbn/9781910443705; Veterinary Pharmacology and Therapeutics — ISBN 9781118855829, https://openlibrary.org/isbn/9781118855829 |
Every held source for this drug and species, as printed. Where they differ, both are shown — the choice is yours, not ours.
| Dose (mg/kg) | Route | Source | As printed |
|---|---|---|---|
| 2 | PO | BSAVA Small Animal Formulary, 10th ed — Part A (Canine and Feline)p.263 | 2 mg/kg p.o. q14d for 2 doses then q1month for a total maximum of 7 doses. Should be given immed |
Figures are transcribed from the cited page or table of each held edition and are shown for reference only. They are not dose recommendations, they do not feed the calculator, and none has been reviewed by a veterinarian.
Need the exact dose for your patient?
These ranges are per kg. Enter your dog's weight to get the precise dose and draw-up volume — unit and concentration math done for you.
Selective COX-2 inhibitor with extremely long half-life (44 days in dogs). Once-monthly dosing after initial loading.
Dogs only (EU-approved). Very long half-life — cannot rapidly discontinue if adverse effects. Not for dogs <12 months or <5kg. Monitor hepatic/renal. Maximum 7 doses (6.5 months).
Species-specific contraindications and adverse-reaction reports for dogs may differ from canine / feline reference data — consult the primary citations listed with each rule.
Mavacoxib dose range in dogs, with cited source references: PO 2 mg/kg Day 0, Day 14, then monthly (max 7 doses). Reference ranges from cited sources — verify against current literature before clinical use.
Documented routes for Mavacoxib in dogs: PO.
Cited course lengths for Mavacoxib in dogs include: Maximum 6.5 months continuous treatment. Duration depends on the indication — match it to the specific dose rule in the table above.
Mavacoxib is indicated in dogs for: Osteoarthritis (long-term).
These are general warnings for Mavacoxib across species; consult the dog dosing table above for species-specific guidance. Dogs only (EU-approved). Very long half-life — cannot rapidly discontinue if adverse effects. Not for dogs <12 months or <5kg. Monitor hepatic/renal. Maximum 7 doses (6.5 months).
Why a species-specific page? Mavacoxib pharmacokinetics differ across species: dose ranges, intervals, and route preferences are not interchangeable. Cross-extrapolation from canine doses is unsafe in dogs — the rules above are the citations specific to this species, not generic recommendations.
Sourced from published veterinary references; awaiting credentialed clinical reviewer. See our editorial process. Reference only — not veterinary advice.